Genmab A/S, GE9:HAN directors and dealings

Price (EUR)214.20
Today's Change0.90 / 0.42%
Shares traded--
1 Year change-21.25%
Beta--

Data delayed at least 15 minutes, as of Nov 08 2024 16:25 GMT.

More ▼

Add to Your Portfolio

Name

Currency

Directors & dealings data is unavailable for this security.

Directors & Officers

Click or tap a row for biographies

Name	Title	Compensation	Age	Officer since
Deirdre Connelly	Independent Chairman of the Board	1.70mDKK	63	2018
Jan Van De Winkel	President, Chief Executive Officer	20.00mDKK	63	2010
Pernille Erenbjerg	Independent Deputy Chairman of the Board	1.30mDKK	56	2015
Anthony Pagano	Chief Financial Officer, Executive Vice President	7.10mDKK	46	2020
Christopher Cozic	Executive Vice President, Chief People Officer	5.40mDKK	46	2021
Rayne Waller	Executive Vice President, Chief Technology Officer	--	--	2024
Tahamtan Ahmadi	Executive Vice President, Chief Medical Officer, Head of Experimental Medicines	7.70mDKK	51	2021
Brad Bailey	Executive Vice President and Chief Commercial Officer	--	--	2024
Judith Klimovsky	Executive Vice President, Chief Development Officer	8.10mDKK	67	2017
Birgitte Stephensen	Executive Vice President, Chief Legal Officer	4.40mDKK	63	2010
Martine Van Vugt	Executive Vice President, Chief Strategy Officer	4.80mDKK	53	2023
Takahiro Hamatani	Non-Independent Director, Employee Elected	600.00kDKK	49	2022
Anders Pedersen	Non-Independent Director	1.10mDKK	72	2005
Martin Schultz	Non-Independent Director, Employee Elected	600.00kDKK	48	2022
Mijke Zachariasse	Non-Independent Director, Employee Elected	600.00kDKK	49	2019
Rolf Hoffmann	Independent Director	900.00kDKK	65	2017
Elizabeth O'farrell	Independent Director	900.00kDKK	59	2022
Paolo Paoletti	Independent Director	900.00kDKK	73	2015
Andrew Carlsen	Vice President, Head of Investor Relations	--	--	2021

More ▼

Data Provided by LSEG

All markets data located on FT.com is subject to the FT Terms & Conditions

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.

Genmab A/S

Select symbol

Genmab A/S

ApplyActions

Your alerts

Directors & Officers